Noticias de BIIB_US

Mercado

Noticias del mercado

Últimas noticias sobre BIIB_US — 494 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: BIIB_US ✕ 494 resultados
02/09/2026 BIIB_US — GuruFocus
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors
02/09/2026 BIIB_US — MarketWatch
Biogen Inc. stock outperforms competitors on strong trading day
02/09/2026 BIIB_US — AD HOC NEWS
Biogen Inc. stock gains as Canadian Alzheimer reimbursement supports outlook

Biogen Inc. stock is trading above 219 USD as investors weigh fresh Canadian support for Alzheimer d

01/09/2026 BIIB_US — AD HOC NEWS
Biogen Inc. stock gains as Canada backs reimbursement for Alzheimer drug Leqembi

Biogen Inc. stock is trading higher after Canada’s national drug agency recommended public reimburse

01/09/2026 BIIB_US — 24/7 Wall St.
Biogen (BIIB) Earnings History & Trends

Biogen (BIIB) quarterly earnings trends: EPS and revenue history versus Street estimates across all reported quarters, from SEC filings.

01/09/2026 BIIB_US — Stock Titan
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News
01/09/2026 BIIB_US — Via Ritzau
Biogen Inc.
01/09/2026 BIIB_US — GlobeNewswire
Stoke Therapeutics and Biogen Announce Presentations of
01/09/2026 BIIB_US — Business Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
01/09/2026 BIIB_US — NTB Kommunikasjon
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
31/08/2026 BIIB_US — Quiver Quantitative
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients

Canada's Drug Agency recommends public reimbursement for LEQEMBI® in eligible Alzheimer’s patients,

31/08/2026 BIIB_US — GlobeNewswire
Canada’s Drug Agency Issues Final Positive Recommendation
31/08/2026 BIIB_US — AD HOC NEWS
Biogen stock draws attention as Canadian panel backs Alzheimer’s drug access

Biogen stock is in focus after a Canadian health agency issued a final positive recommendation suppo

31/08/2026 BIIB_US — DirectorsTalk Interviews
Biogen Inc. (BIIB) Stock Report: Analyst Ratings Signal Potential Upside Of Over 8%
31/08/2026 BIIB_US — Biogen
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
29/08/2026 BIIB_US — AD HOC NEWS ES ← EN
Las acciones de Biogen mantienen ganancias después de un sólido segundo trimestre y elevaron la orientación para 2026

Biogen stock is trading above $220 after a second quarter 2026 earnings beat and a higher full-year

28/08/2026 BIIB_US — MarketWatch
Biogen Inc. stock underperforms Friday when compared to competitors
28/08/2026 BIIB_US — Value Research
Biogen Inc. (BIIB) Shareholding Pattern – Promoters, FIIs & DIIs
28/08/2026 BIIB_US — Yahoo Finance
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
27/08/2026 BIIB_US — investors.biogen.com
Biogen to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Página 2 de 25